Home › Funds › Commodore Capital LP › SABS

Commodore Capital LP position in SABS

SAB BIOTHERAPEUTICS INC · Health Care

Commodore Capital LP reported holding 2,870,000 shares of SABS (SAB BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$11.2M, representing 0.67% of its reported portfolio and ranking #26 among its reported holdings. Commodore Capital LP has disclosed SABS holdings in 6 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)2.87M sh
Reported value held$11.19M
Portfolio Weight0.67%
First reportedQ4 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Commodore Capital LP's SABS position evolved

Commodore Capital LP first disclosed a stake in SABS in Q4 2023 at 1,831,746 shares (US$1.3M). The position peaked in Q1 2026 at 4,401,500 shares, worth US$16.9M. Across 6 filings, Commodore Capital LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 2,870,000 shares valued at US$11.2M — a reduction of -1,531,500 shares quarter over quarter.. Notable position changes include a 90% trim in Q1 2024 (shares fell 32% over the following quarter), a 35% trim in Q2 2026 (shares fell 19% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 1.83M $1.26M New
Q1 2024 183.17K $831.61K Reduce
Q3 2025 4.40M $8.85M New
Q4 2025 4.40M $16.46M Hold
Q1 2026 4.40M $16.86M Hold
Q2 2026 2.87M $11.19M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About SABS and 13F data

SABS (SAB BIOTHERAPEUTICS INC) is a Health Care company. 77 other funds we track also report a position in SABS — the largest reported positions include Caligan Partners LP (US$31.1M), Vivo Capital, LLC (US$28.5M), Spruce Street Capital LP (US$8.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding SABS

All SABS fund holders →

FAQ

How long has Commodore Capital LP held SABS?

Commodore Capital LP has disclosed SABS holdings in 6 of the last 11 reported quarters, going back to Q4 2023.

What is Commodore Capital LP's current position in SABS?

As of Q2 2026, Commodore Capital LP holds 2.87M shares of SABS (SAB BIOTHERAPEUTICS INC), valued at $11.19M, representing 0.67% of its reported portfolio and ranking #26.

Has Commodore Capital LP been buying or selling SABS?

In the latest 13F filing (Q2 2026), Commodore Capital LP reduced its position in SABS. The position peaked in Q1 2026 at 4.40M shares.

Which other funds hold SABS?

Other major institutional holders of SABS include Caligan Partners LP, Vivo Capital, LLC, Spruce Street Capital LP, among 77 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.